Cargando…
Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma
BACKGROUND: Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). HBV DNA can get integrated into the hepatocyte genome to promote carcinogenesis. However, the precise mechanism by which the integrated HBV genome promotes HCC has not been elucidated. AIM: To analyze the feature...
Autores principales: | Kojima, Ryuta, Nakamoto, Shingo, Kogure, Tadayoshi, Ma, Yaojia, Ogawa, Keita, Iwanaga, Terunao, Qiang, Na, Ao, Junjie, Nakagawa, Ryo, Muroyama, Ryosuke, Nakamura, Masato, Chiba, Tetsuhiro, Kato, Jun, Kato, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311580/ https://www.ncbi.nlm.nih.gov/pubmed/37396703 http://dx.doi.org/10.5501/wjv.v12.i3.209 |
Ejemplares similares
-
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus
por: Ma, Yaojia, et al.
Publicado: (2022) -
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma
por: Ao, Junjie, et al.
Publicado: (2021) -
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience
por: Ogawa, Keita, et al.
Publicado: (2022) -
Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer
por: Imai, Yushi, et al.
Publicado: (2020) -
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
por: Yumita, Sae, et al.
Publicado: (2023)